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A GGGGCC repeat expansion in the C9orf72 gene was recently identiﬁed as a major cause of familial and
sporadic amyotrophic lateral sclerosis and frontotemporal dementia. There is suggestion that these ex-
pansions may be a rare cause of parkinsonian disorders such as progressive supranuclear palsy (PSP),
multiple system atrophy (MSA), and corticobasal degeneration (CBD). Screening the C9orf72 gene in 37
patients with features of corticobasal syndrome (CBS) detected an expansion in 3 patients, conﬁrmed by
Southern blotting. In a series of 22 patients with clinically diagnosed PSP, we found 1 patient with an
intermediate repeat length. We also screened for the C9orf72 expansion in a large series of neuro-
pathologically conﬁrmed samples with MSA (n ¼ 96), PSP (n ¼ 177), and CBD (n ¼ 18). Patients were
found with no more than 22 GGGGCC repeats. Although these results still need to be conﬁrmed in a
larger cohort of CBS and/or CBD patients, these data suggest that in the presence of a family history and/
or motor neuron disease features, patients with CBS or clinical PSP should be screened for the C9orf72
repeat expansion. In addition, we conﬁrm that the C9orf72 expansions are not associated with patho-
logically conﬁrmed MSA, PSP, or CBD in a large series of cases.
 2015 The Authors. Published by Elsevier Inc. All rights reserved.1. Introduction
The identiﬁcation of a GGGGCC repeat expansion in the
C9orf72 gene (OMIM *614260) has been an important break-
through in the diagnosis and understanding of neurodegenera-
tive disorders. Expansions in this gene have primarily been
identiﬁed in familial and sporadic amyotrophic lateral sclerosis
(ALS; OMIM #105400) and frontotemporal dementia (FTD;e CC BY license (http://
interest.




Published by Elsevier Inc. All righOMIM #600274) (DeJesus-Hernandez et al., 2011; Renton et al.,
2011). A greater frequency of expansions has been observed in
the Finnish and Northern European populations (Mok et al.,
2012). Neuropathologically, TAR DNA-binding protein-43 and
p62 inclusions are present in samples carrying C9orf72 expan-
sions but our knowledge of the neuropathology associated with
this genetic abnormality is expanding (Bieniek et al., 2013;
Neumann, 2013).
Progressive supranuclear palsy (PSP; OMIM #601104), multiple
system atrophy (MSA; OMIM #146500), and corticobasal degener-
ation (CBD) are collectively referred as atypical parkinsonian dis-
orders, and they each have speciﬁc and validated diagnostic criteria
(Armstrong et al., 2013; Gilman et al., 2008; Litvan et al., 1996).
Patients with MSA present with a combination of cerebellar
dysfunction, parkinsonism, and autonomic dysfunction and arets reserved.
Table 1
Results of C9orf72 repeat expansion screening in atypical parkinsonism
Diagnosis Number of samples Expanded
MSA (pathologically conﬁrmed) 96 0
CBD (pathologically conﬁrmed) 18 0
PSP (pathologically conﬁrmed) 177 0
CBS (clinical) 37 3 (p < 0.001a)
PSP (clinical) 22 1 (27 repeats)
British controls (clinical) 7579 11
Key: CBD, corticobasal degeneration; CBS, corticobasal syndrome; MSA, multiple
system atrophy; PSP, progressive supranuclear palsy.
a Fisher exact test comparing our CBS cohort with previously published British




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































L.V. Schottlaender et al. / Neurobiology of Aging 36 (2015) 1221.e1e1221.e61221.e2pathologically characterized by alpha-synuclein immunoreactive
glial cytoplasmic inclusions and neuronal loss in the olivoponto-
cerebellar and striatonigral systems (Ahmed et al., 2012). Postural
instability and supranuclear gaze palsy are the salient features in
PSP, which exhibits predominantly 4-repeat tau in a characteristic
distribution including tufted astrocytes and coiled bodies (Williams
and Lees, 2009). CBD is pathologically characterized by cortical and
striatal 4-repeat tau deposition with astrocytic plaques being the
pathologic hallmark (Ling et al., 2010). Corticobasal syndrome (CBS)
consists of a constellation of extrapyramidal and frontoparietal
cortical features. CBS is the classic clinical presentation of CBD, but
many CBS cases turn out to have alternate neuropathology.
The genetic understanding of the atypical parkinsonian disorders,
MSA, PSP, and CBD has lagged behind the commoner neurodegen-
erative conditions of ALS, FTD, and Parkinson’s disease (PD). MSA has
been linked to variants in the SNCA gene (Al-Chalabi et al., 2009; Kiely
et al., 2013; Ross et al., 2010; Scholz et al., 2009). More recently,
variants in COQ2 has been proposed as a cause of familial MSA and a
risk factor for sporadic clinically diagnosed MSA in the Japanese
population (Multiple-System Atrophy Research Collaboration, 2013),
which has failed to be replicated so far (Jeon et al., 2014;
Schottlaender et al., 2014; Sharma et al., 2014). Further work could
not identify MSA risk genes (Segarane et al., 2009), and a genome-
wide association study in MSA is ongoing (Sailer A, personal
communication). A genome-wide association study in PSP has
conﬁrmed an association with variants in MAPT and has shown a
signiﬁcant signal with variants in EIF2AK3, STX6, and MOBP
(Höglinger et al., 2011), but further research is needed to understand
these ﬁndings. The H1/H1MAPT haplotype is associatedwith PSP and
CBD and likewiseMAPT variants such as p.N410H (Kouri et al., 2014)
and p.A152T have been linked to pathologically conﬁrmed CBD and
PSP (Houlden et al., 2001; Kara et al., 2012).
Overlap of the clinical features of PSP and CBS are not uncom-
mon, although CBD can have a clinical phenotype of classic PSP,
which is known as Richardson syndrome, and rarely PSP may
present with CBS (Ling et al., 2010, 2014). In addition, atypical
parkinsonian disorders and PD often cluster in pedigrees; however,
this is not often inherited in a dominant fashion.
Taking a good family history is essential in the diagnosis of
neurodegenerative diseases. Patients with ALS that carry C9orf72
expansions commonly have a history of FTD and/or a family history
of other neurodegenerative or neuropsychiatric disorder (Byrne
et al., 2012, 2013; Fallis and Hardiman, 2009). Numerous ALS and
FTD series have now been screened for C9orf72 expansions
(Rademakers, 2012). The expansions have also been rarely identi-
ﬁed in PD, CBS, PSP, MSA-cerebellar type, and dementia with Lewy
bodies (Dejesus-Hernandez et al., 2013; Lesage et al., 2013;
Lindquist et al., 2013; Snowden et al., 2012; Ticozzi et al., 2014).
The expansion has also been detected in some families with Alz-
heimer’s disease (AD) but few had pathologic conﬁrmation (Beck
et al., 2013; Harms et al., 2013; Majounie et al., 2012; Xi et al.,
2012). C9orf72 expansions have been identiﬁed in nondemented
Fig. 1. Example of fragment analysis in C9orf72. Upper left ﬁgure showing heterozygous expansion by RP-PCR, lower left showing unexpanded allele by sizing PCR. Figure on the
right is a Southern blot (with BsU36I restriction digest) showing 2 of the expanded CBS cases. Abbreviations: C, control no expansion; CBS, corticobasal syndrome; E, expanded; PCR,
polymerase chain reaction; RP-PCR, repeat-primed polymerase chain reaction.
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(Beck et al., 2013; Cooper-Knock et al., 2013; Galimberti et al., 2014).
Based on the large heterogeneity of patients with a C9orf72
repeat expansion we aim to assess the frequency of this genetic
variation in a large series of patients with atypical parkinsonism.
2. Methods
2.1. Informed consent and standard protocol approvals
Informed consent was obtained for genetic analysis from all
patients. Brain tissue from neuropathologically conﬁrmed samples
was obtained from the Queen Square, Harvard, Maryland and the
Netherlands Brain Banks (UCLH ethics approval (UG2UPDj04/
Q0505/2). Tissue is stored in the Queen Square Brain Bank (QSBB)
under a license from the Human Tissue Authority and has been
donated for research according to protocols approved by the NRES
committee London-Central.Fig. 2. Top ﬁgure: RP-PCR showing the case with heterozygous 27 repeats on 1 allele, 5 repe
digest) of different repeat sizes from 20 to 27 showing the Southern blot appearance of di
conﬁrmed by ﬂuorescent PCR of the C9orf72 repeat and fragment analysis. Abbreviations: P2.2. Sample and DNA extraction
Screening for the C9orf72 expansion was performed in both
clinically diagnosed atypical parkinsonism patients as well as
pathologically conﬁrmed samples. The clinically diagnosed cohort
included CBS (n ¼ 37) and PSP (n ¼ 22) samples, and the patho-
logically conﬁrmed series comprised MSA (n ¼ 96), PSP (n ¼ 177),
and CBD (n ¼ 18) samples.
Genomic DNA was extracted from peripheral blood using Flex-
igene extraction kit and Autopure LS extraction system (Qiagen,
Venlo, the Netherlands) and from brain tissue using the DNeasy
Tissue Kit (Qiagen, Hilden, Germany) according to the manufac-
turer’s instructions.
2.3. Repeat-primed polymerase chain reaction
To provide a qualitative assessment of the presence of an
expanded GGGGCC hexanucleotide repeat in C9orf72, we performedats on the other. Bottom ﬁgure: Southern blot conﬁrmation (with BamHI/EcoRI double-
fferent fragments. Numbers ¼ number of C9orf72 repeats. Number of repeats was also
CR, polymerase chain reaction; RP-PCR, repeat-primed polymerase chain reaction.
Fig. 3. Family tree of the patient (II-3, arrow) with a 27-repeat allele. The patient’s
father (I-1) and sister (II-1) were diagnosed with dementia, and the patient’s mother (I-
2) was diagnosed with Parkinson’s disease. The clinical features are discussed further
in Table 2 and in the text.
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ampliﬁed with a PCR reaction performed in the presence of 1 M
betaine, with Extensor long PCR master mix (Thermo Scientiﬁc),
using a previously described cycling program (Gijselinck et al., 2012).
Primer sequences using one ﬂuorescently labeled primer were used
as previously published (DeJesus-Hernandez et al., 2011). A second
sizing PCR was also used to size alleles of<30 repeats. This PCR used
previously published primers (DeJesus-Hernandez et al., 2011) in a
reaction with Extensor long PCR master mix (Thermo Scientiﬁc)
supplemented with betaine, dimethyl sulfoxide, magnesium chlo-
ride, and 7-deaza-2-deoxy GTP. All PCR products were analyzed by
fragment length analysis on an automated ABI3730 DNA-analyzer,
and allele identiﬁcation and scoring was accomplished using Gene-
Mapper v3.7 software (ABI).
2.4. Southern blotting
Conﬁrmation of expansions and intermediate repeats was per-
formed by Southern blotting with a 1 kb single copy probe as
previously described (Fratta et al., 2013) but using BsU36I or
BamHI/EcoRI restriction enzyme digests that generate a 6.2 kb or
2.4 kb band for unexpanded alleles, respectively, rather than the
EcoRI digest used previously that generates an 8 kb band.
3. Results
Among clinically diagnosed patients, a pathologic expansion in
C9orf72 was detected in 3 CBS patients, representing a signiﬁcant
association when compared with published British controls (p <
0.001) (Beck et al., 2013) (Fig. 1, Table 1). A single patient with
clinically diagnosed PSPwas found to carry an intermediate allele of
27 repeat length in C9orf72 (Fig. 2). All these expansions were
conﬁrmed by Southern blot (Figs. 1 and 2).
All pathologically conﬁrmed MSA, PSP, and CBD samples were
found not to have pathologic expansions. No patient had more than
22 GGGGCC C9orf72 repeats (range, 2e22 repeats).
Clinically, the 3 patients that carry a large C9orf72 expansion
presented with a CBS phenotype classiﬁed as probable CBD ac-
cording to consensus criteria. One of them had additional motor-
neuron features and the other 2 had dysphagia and dysarthria as
salient features. Two expansion carriers had a family history of
dementia. The patient with a 27-repeat allele had an onset later in
life, presented and progressed as typical PSP, and had a family
history of dementia as well as Parkinson’s disease.
The full clinical characteristics of the patients with expansions
are described in Table 2. The family tree of the patient with an in-
termediate repeat is presented in Fig. 3.
4. Discussion
In this study, we identiﬁed a C9orf72 expansion in 3 patients
with a clinical history consistent with CBS and 1 intermediate
expansion in a patient with a clinical history of PSP. The identiﬁ-
cation of CBS patients with C9orf72 repeat expansions is an
important point to portray to clinicians and diagnostic labora-
tories. A positive family history was present in 3 of 4 of these
patients. This suggests the diagnostic workup of CBS patients with
a possible and/or probable family history, in the presence of
motor-neuron features, should include screening for C9orf72 ex-
pansions (Ticozzi et al., 2014). The counseling of other family
members will be an important issue to discuss in depth given the
reduced penetrance and the very rare identiﬁcation of the
expanded repeat in elderly controls (Beck et al., 2013; Galimberti
et al., 2014). Furthermore, C9orf72 repeat expansions may have
relevance in patients with CBS and other neurodegenerativedisorders, which can have heterogeneous underlying neuropa-
thology (Kouri et al., 2011; Ling et al., 2010). The expansion should
also be screened in patients with familial AD as FTD may have an
amnestic AD-like presentation.
In addition, we found the absence of C9orf72 repeat expan-
sions in the largest series of pathologically conﬁrmed MSA, PSP,
and CBD samples screened to date. This adds to our knowledge of
this genetic abnormality and helps to deﬁne the spectrum of
C9orf72 expansion-associated neuropathology. Other unknown
and likely poorly penetrant genetic variations consisting of SNPs
or repeat expansions in other genes may still be associated with
these disorders, although any new genetic ﬁnding in MSA would
probably differ from PSP and CBD in view of their pathologic
differences.
The pathologic cutoff for C9orf72 repeat expansions remains
debatable. Repeat sizes between 20 and 30 are commonly referred
to as intermediate alleles and are of uncertain signiﬁcance;
although above 30 repeats are frequently considered pathologic.
FTD patients with 20e22 repeats have been reported in the past
without any signiﬁcant clinical difference in the FTD phenotype
compared with those with large expansion (Gómez-Tortosa et al.,
2013). The C9orf72 intermediate repeat copies were found to be a
signiﬁcant risk factor for PD in a Spanish study (Nuytemans et al.,
2013) but later could not be conﬁrmed in a pathologically
conﬁrmed PD cohort (Nuytemans et al., 2014). There is also debate
in the ﬁeld that expansions in C9orf72 are actually diseasemodiﬁers
and not disease causative. This belief is reinforced by the fact that
double mutants have been identiﬁed (Ferrari et al., 2012; King et al.,
2013; Mignarri et al., 2014; van Blitterswijk et al., 2013). It is also
important to this study that MAPT has been found mutated in PSP
and GRN in CBSdboth of which are FTD-associated genes (Benussi
et al., 2009; Dopper et al., 2011; Höglinger et al., 2011). Defects in
these genes in our cases had been previously excluded.
In this study, the signiﬁcance of the individual with an inter-
mediate allele of 27 repeats in C9orf72 is unknown, although the
late onset PSP phenotype and the family history may be suggestive
of pathogenicity. Unfortunately, we are unable to investigate
segregation in this family because of lack of DNA in the deceased
patients.
The issue of penetrance, intermediate alleles, and the true
pathologic cutoff will be of signiﬁcant importance in the future
from a diagnostic point of view. Predictive counseling of unaffected
individuals in families will rely on a future understanding of the
L.V. Schottlaender et al. / Neurobiology of Aging 36 (2015) 1221.e1e1221.e6 1221.e5mechanistic basis of the expansion and the differences in risk
conferred by repeat size variation.
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